Evinacumab

Drug Profile

Evinacumab

Alternative Names: REGN-1500

Latest Information Update: 14 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action ANGPTL3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperlipoproteinaemia type IIa

Most Recent Events

  • 08 Jun 2017 Regeneron Pharmaceuticals plans a phase II trial for Hypercholesterolaemia (NCT03175367)
  • 24 May 2017 Pharmacodynamics data from preclinical study in Atherosclerosis released by Regeneron Pharmaceuticals
  • 01 May 2017 Regeneron Pharmaceuticals initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03146416)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top